[Federal Register Volume 64, Number 123 (Monday, June 28, 1999)]
[Notices]
[Page 34682]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-16265]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Registration

    By Notice dated February 5, 1999, and published in the Federal 
Register on February 26, 1999, (64 FR 9542), Novartis Pharmaceuticals 
Corp., 59 Route 10, East Hanoever, New Jersey 07936, made application 
by renewal to the Drug Enforcement Administration (DEA) to be 
registered as a bulk manufacturer of methylphenidate (1724), a basic 
class of controlled substance listed in Schedule II.
    The firm plans to manufacture finished product for distribution to 
its customers.
    DEA has considered the factors in Title 21, United States Code, 
Section 823(a) and determined that the registration of Novartis 
Pharmaceuticals Corp. to manufacture methylphenidate is consistent with 
the public interest at this time. DEA has investigated Novartis 
Pharmaceuticals Corp. on a regular basis to ensure that the company's 
continued registration is consistent with the public interest. These 
investigations have included inspection and testing of the company's 
physical security systems, audits of the company's records, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823 and 28 CFR sections 0.100 and 0.104, the Deputy 
Assistant Administrator, Office of Diversion Control, hereby orders 
that the application submitted by the above firm for registration as a 
bulk manufacturer of the basic class of controlled substance listed 
above is granted.

    Dated: June 15, 1999.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 99-16265 Filed 6-25-99; 8:45 am]
BILLING CODE 4410-09-M